A phase II study of laquinimod in Crohn's disease

OBJECTIVE: Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. This dose escalation study evaluated the safety and efficacy of laquinimod as induction therapy in patients with a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gut
Hlavní autoři: D'Haens, Geert, Sandborn, William J, Colombel, Jean Frederic, Rutgeerts, Paul, Brown, Kurt, Barkay, Hadas, Sakov, Anat, Haviv, Asi, Feagan, Brian G
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2015
Témata:
Inflammatory Bowel Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515993/
https://ncbi.nlm.nih.gov/pubmed/25281416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2014-307118
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky